Sensus Healthcare initiated with a Buy at Lake Street

Lake Street initiated coverage of Sensus Healthcare (SRTS) with a Buy rating and $18 price target Sensus’ superficial radiation therapy is a non-invasive treatment with no surgical scarring or need for reconstructive surgery that allows patients to maintain their ordinary activities while undergoing treatment, which cannot be said for Mohs micrographic surgery and other surgical options that dominate the non-melanoma skin cancer treatment landscape, the analyst tells investors. As of today, Sensus “stands alone with no SRT competition and we argue none likely to emerge,” the analyst added.